Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1213-1218

  Nishikawa, Hiroki ^a   Nishijima, Norihiro ^a   Arimoto, Akira ^a   Inuzuka, Tadashi ^b   Kita, Ryuichi ^a   Kimura, Toru ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Entecavir; Hepatitis B virus; Hepatocellular carcinoma; Prognostic factor

Indexed keywords

ADEFOVIR; ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; ENTECAVIR; HEPATITIS B (E) ANTIGEN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DEATH; ENZYME IMMUNOASSAY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; SPLENOMEGALY;

EID: 84884479170     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1578     Document Type: Article

References (35)

1. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
2. de Lope CR, Tremosini S, Forner A, et al: Management of HCC. J Hepatol 56 (Suppl 1): S75-S87, 2012.
3. El-Serag HB: Hepatocellular carcinoma. N Engl J Med365: 1118-1127, 2011.
4. Chan HL and Sung JJ: Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 26: 153-161, 2006.
5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ and BellBP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529-538, 2006.
6. Belongia EA, Costa J, Gareen IF, et al: NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements 25: 1-29, 2008.
7. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T and OsakiY: Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol 42: 151-160, 2013.
8. Lencioni R: Loco-regional treatment of hepatocellular carcinoma. Hepatology 52: 762-773, 2010.
9. Lai CL, Chien RN, Leung NW, et al: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339: 61-68, 1998.
10. Dienstag JL, Schiff ER, Wright TL, et al: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med341: 1256-1263, 1999.
11. Lok AS, Lai CL, Leung N, et al: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology125: 1714-1722, 2003.
12. Marcellin P, Chang TT, Lim SG, et al: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. NEngl J Med 348: 808-816, 2003.
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al: Adefovir Dipivoxil 438 Study Group: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348: 800-807, 2003.
14. Chang TT, Gish RG, de Man R, et al: BEHoLD AI463022 Study Group: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001-1110, 2006.
15. Lai CL, Shouval D, Lok AS, et al: BEHoLD AI463027 Study Group: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354: 1011-1120, 2006.
16. Zoulim F: Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 31 (Suppl 1): S111-S116, 2011.
17. Leung N, Peng CY, Hann HW, et al: Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 49: 72-79, 2009.
18. Chang TT, Lai CL, Kew Yoon S, et al: Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51: 422-430, 2010.
19. Ide T, Sata M, Chayama K, et al: Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol Int 4: 594-600, 2010.
20. Wong GL, Chan HL, Mak CH, et al: Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology: Feb 6, 2013 (Epub ahead of print). doi: 10.1002/hep.26301.
21. Hosaka T, Suzuki F, Kobayashi M, et al: Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology: 58: 98-107, 2013.
22. Shakado S, Watanabe H, Tanaka T, et al: Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B. Hepatol Int 2: 361-369, 2008.
23. Ohishi W and Chayama K: Treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Res 42: 219-225, 2012.
24. Bruix J and Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
25. No authors listed: The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg 19: 98-129, 1989.
26. Lo CM, Liu CL, Chan SC, et al: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245: 831-842, 2007.
27. Chan AC, Chok KS, Yuen WK, et al: Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 146: 675-681, 2011.
28. Du Y, Su T, Ding Y and Cao G: Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon 12: e6031, 2012.
29. Sun HC, Zhang W, Qin LX, et al: Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 47: 684-690, 2007.
30. Yao D, Jiang D, Huang Z, et al: Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 88: 761-769, 2000.
31. Zhang JB, Chen Y, Zhang B, et al: Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol 23: 787-793, 2011.
32. Ono A, Suzuki F, Kawamura Y, et al: Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol 57: 508-514, 2012.
33. Huang G, Yang Y, Shen F, et al: Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol20: 1482-1490, 2013.
34. Chen L, Zhang Q, Chang W, Du Y, Zhang H and Cao G: Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 48: 1977-1987, 2012.
35. Xia F, Lai EC, Lau WY, et al: High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Ann Surg Oncol 19: 1284-1291, 2012.